Our findings present some experimental evidence that the reduction of IL-1β, TNF-α, and IL-16 in the serum and synovial tissue and the reduction of lymphocyte proliferation might be of potential clinical interest in RA treatment. The gene discussed is IL16; the disease is rheumatoid arthritis.